cho_logo_symbol_border
  • (800) 266-7207 | 30 Wall St. 8th Floor New York, NY 10005
  • Mon - Fri: 8:00 am - 5:00 pm

Day: September 26, 2022

Omicron BA.2.75.2, the ‘Most Resistant’ Variant to Date

179 Views1 Comment

As time goes by and the Coronavirus continues to mutate, the world keeps having to pivot quickly to continue battling this never-ending virus. “Since the COVID-19 pandemic began, health officials have warned that the biggest barrier to controlling the virus would be its ability to mutate

Read More

Disclaimer

Clear Health Pass Safe Harbor Exemption
The information on this website does not constitute an offer to sell or solicitation of an offer to buy securities by anyone in any jurisdiction which would be considered unlawful. Clear Health Pass Holdings, LLC’s offering is under Rule 506(c) of Regulation D and is considered a “safe harbor” for the private offering exemption of Section 4(a)(2) of the Securities Act. To be eligible to receive qualified investment status, you must be an accredited investor as defined by Section 2(15)(ii) of the Securities Act of 1933.

© 2023 Clear Health Pass Holdings™, LLC., All trademark references are trademarks of either the Clear Health Pass Holdings, LLC or their respective owners.

 

Our Journey to $1B+ Valuation

 

Disrupting Healthcare Testing / Diagnostics Early Detection of Cancer,
Chronic Conditions, Disease, Unlocking Anti-Aging Genomics & Promoting Longevity.

 

FUNDING GOAL $20,000,000

Funding Goal $20,000,000

20%

Click here to Download Our Investment Package

Skip to content